还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

3 K9 O1 r+ f& L7 P0 G" B- a                               
登录/注册后可看大图

8 c% z: D2 i$ s9 ]请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


Sub-category:
1 [3 M4 A( r1 x% vMolecular Targets
+ Q  N6 I4 X5 t/ `  `: i
/ k$ `# i& C/ A! Z6 n4 c
Category:
Tumor Biology
' A0 p/ H( A: c( O5 ?
6 _+ M% @/ a' Y/ V& r
! u0 N( }7 q8 t$ v# W. [Meeting:
) s3 F9 R" \) s% ^2011 ASCO Annual Meeting

) M3 _* D% l4 m! ^0 G+ o' ~
Session Type and Session Title:
% t  J6 }1 c* J4 }; bPoster Discussion Session, Tumor Biology

4 q. L8 p- |! A0 w
Abstract No:
10517
9 k% g2 h1 |% w0 r, I

Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)


8 @: y- I+ Q- K6 ]  o! ZAuthor(s):
5 m3 n8 j2 o0 |7 m& eJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
' B# |: r5 K3 U  ~6 h( p
9 L$ Y6 x. K2 S3 Z- h: d' N4 I
$ W  u# F6 |$ S2 O
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& \& G; n1 R. m4 O. y  n! F" n, r
Abstract Disclosures
6 e$ d# \  R+ O. o" G2 ~$ O
Abstract:
; w2 n, N% D' [5 Y" Q( p4 X

. w. |# d; i. o( uBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
& P7 A5 P, z% J; K

* t; ~* \  V* }  Y# s

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

# _/ }" R2 X- o" n" A% _6 O没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

7 G! s6 B' Q$ Y0 J% u2 l                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
/ T+ s- `" q: Y. ~# p' ]0 I
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊